ライフサイエンスコーパス: tromethamine

1 ically known Abeta channel blockers zinc and tromethamine.

2 by AbetaP calcium channel blockers Zn2+ and tromethamine.

3 bicarbonate and decreased after Carbicarb or tromethamine.

4 l anti-inflammatory drugs, such as ketorolac tromethamine 0.5% and diclofenac sodium 0.1%, offer comp

5 xclusive eye drops administration (ketorolac tromethamine 0.5% and sodium diclofenac 0.1%) also showe

6 ears), prednisolone acetate 1%, or ketorolac tromethamine 0.5% eye drops 4 times per day for 5 days c

7 To determine the effect of ketorolac tromethamine 0.5% in preventing post-phacoemulsification

8 Based on our findings, topical ketorolac tromethamine 0.5% is not effective in the prevention of

9 Eyes were randomized to ketorolac tromethamine, 0.45% (Acuvail), or placebo 4 times daily

10 Topical ketorolac tromethamine, 0.45%, significantly lowered aqueous IL-8

11 mbination of prednisolone, 1%, and ketorolac tromethamine, 0.5%, with or without preoperative initiat

12 bleeding between the groups taking ketorolac tromethamine (33 of 1304 patients [2.5%]) and the contro

13 steroidal anti-inflammatory agents ketorolac tromethamine and diclofenac sodium augmented the effect

14 ine, mefenamic acid, intramuscular ketorolac tromethamine, and potassium diclofenac) also showed a st

15 , polyethylene glycol (PEG), polysorbate and tromethamine are excipients.

16 hydrochloride as an analgesic and ketorolac tromethamine as an NSAID.

17 te as a CO2-generating buffer, Carbicarb and tromethamine as CO2-consuming buffers, or hypertonic sal

18 as been associated with parenteral ketorolac tromethamine, but the risk that is associated with this

19 Mice treated with 0.5% ketorolac tromethamine for 14 days had high mortality, but when ev

20 s; group II, 0.5% cidofovir + 0.5% ketorolac tromethamine; group III, 0.5% cidofovir + 0.1% diclofena

21 Nonselective (ketorolac tromethamine, ibuprofen, indomethacin), COX-1-selective

22 r diastolic pressure with both Carbicarb and tromethamine in association with significant increases i

23 or 0.5%), 0.1% diclofenac, or 0.5% ketorolac tromethamine in mice with oxygen-induced ischemic retino

24 Preservative-free ketorolac tromethamine is nontoxic to the retinas of rabbits when

25 selective cyclooxygenase inhibitor ketorolac tromethamine (Keto, 10 mm), and combined l-NMMA + Keto (

26 The effects of topical ketorolac tromethamine mouthrinse (0.1%) on gingival crevicular fl

27 er 0.5% or 0.25% preservative-free ketorolac tromethamine ophthalmic solution (0.1 mL) was injected i

28 eath was noted with dexamethasone, ketorolac tromethamine, or diclofenac sodium when used in the pres

29 actinomycin D with dexamethasone, ketorolac tromethamine, or diclofenac sodium.

30 The vascular disrupting agent fosbretabulin tromethamine selectively targets pre-existing tumor vasc

31 rmocapnia (NC, 40 Torr) or HC (80 Torr), +/- tromethamine (THAM) or sodium bicarbonate (HCO3) +/- AC

32 However, addition of ketorolac tromethamine to PGE1 and heparin decreased the incidence

33 In separate experiments, ketorolac tromethamine (Toradol) was given 1 h before GAS infusion

34 In addition, mRNA-1273 also contains tromethamine (trometamol), which has been reported to ca